Web14 apr. 2024 · Keytruda’s sales are gaining from strong momentum in metastatic indications, including in some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, TNBC and MSI-H cancers ... WebHead and Neck Indications: Head and Neck Squamous Cell Carcinoma (HNSCC) Funding Request: First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ≥ 1] as determined by a validated test.
Keytruda European Medicines Agency
Web14 apr. 2024 · Merus N.V. today announced the publication of an abstract for a plenary session oral presentation of interim clinical data on the bispecific antibody petosemtamab in previously treated head and neck squamous cell carcinoma (HNSCC) at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in Orlando, … Web14 jan. 2024 · HPV-related head and neck cancers back in the 1970s or 1980s [accounted for approximately] 15% to 20% [of all head and neck cancers], but now it’s [about] 50%. figary definition
Key opinion leader insights on the head and neck cancer therapy …
Web20 sep. 2024 · In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA ® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. Web25 apr. 2024 · The study included a total of 43 patients with advanced cancers, including cervical cancer, anal cancer, and squamous cell carcinoma of the head and neck. Most (36) of the patients had tumors … Web4 uur geleden · Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for … grinch easy christmas drawings